vs
ANI PHARMACEUTICALS INC（ANIP）与Penguin Solutions, Inc.（PENG）财务数据对比。点击上方公司名可切换其他公司
Penguin Solutions, Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.4倍（$343.1M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 1.5%，领先9.6%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 0.6%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $28.2M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 11.8%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
企鹅解决方案公司旗下的兰波集团以拉姆齐解决方案品牌开展业务，是一家美国企业，业务涵盖个人理财、领导力发展、人际关系管理与职业发展相关产品与服务。该公司由戴夫·拉姆齐与妻子莎伦于1991年创立，总部位于田纳西州富兰克林。
ANIP vs PENG — 直观对比
营收规模更大
PENG
是对方的1.4倍
$247.1M
营收增速更快
ANIP
高出29.1%
0.6%
净利率更高
ANIP
高出9.6%
1.5%
自由现金流更多
ANIP
多$918.0K
$28.2M
两年增速更快
ANIP
近两年复合增速
11.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $343.1M |
| 净利润 | $27.5M | $5.3M |
| 毛利率 | — | 28.0% |
| 营业利润率 | 14.1% | 5.7% |
| 净利率 | 11.1% | 1.5% |
| 营收同比 | 29.6% | 0.6% |
| 净利润同比 | 367.5% | 1.0% |
| 每股收益（稀释后） | $1.14 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPPENG
| Q4 25 | $247.1M | $343.1M | ||
| Q3 25 | $227.8M | $337.9M | ||
| Q2 25 | $211.4M | $324.3M | ||
| Q1 25 | $197.1M | $365.5M | ||
| Q4 24 | $190.6M | $341.1M | ||
| Q3 24 | $148.3M | $284.8M | ||
| Q2 24 | $138.0M | $300.6M | ||
| Q1 24 | $137.4M | — |
净利润ANIPPENG
| Q4 25 | $27.5M | $5.3M | ||
| Q3 25 | $26.6M | $9.4M | ||
| Q2 25 | $8.5M | $2.7M | ||
| Q1 25 | $15.7M | $8.1M | ||
| Q4 24 | $-10.3M | $5.2M | ||
| Q3 24 | $-24.2M | — | ||
| Q2 24 | $-2.3M | $5.6M | ||
| Q1 24 | $18.2M | — |
毛利率ANIPPENG
| Q4 25 | — | 28.0% | ||
| Q3 25 | — | 28.6% | ||
| Q2 25 | — | 29.3% | ||
| Q1 25 | — | 28.6% | ||
| Q4 24 | — | 28.7% | ||
| Q3 24 | — | 28.8% | ||
| Q2 24 | — | 29.6% | ||
| Q1 24 | — | — |
营业利润率ANIPPENG
| Q4 25 | 14.1% | 5.7% | ||
| Q3 25 | 15.9% | 3.7% | ||
| Q2 25 | 6.6% | 3.0% | ||
| Q1 25 | 13.3% | 5.1% | ||
| Q4 24 | -2.3% | 5.1% | ||
| Q3 24 | -13.8% | -1.2% | ||
| Q2 24 | 3.7% | 3.8% | ||
| Q1 24 | 14.8% | — |
净利率ANIPPENG
| Q4 25 | 11.1% | 1.5% | ||
| Q3 25 | 11.7% | 2.8% | ||
| Q2 25 | 4.0% | 0.8% | ||
| Q1 25 | 8.0% | 2.2% | ||
| Q4 24 | -5.4% | 1.5% | ||
| Q3 24 | -16.3% | — | ||
| Q2 24 | -1.7% | 1.9% | ||
| Q1 24 | 13.2% | — |
每股收益（稀释后）ANIPPENG
| Q4 25 | $1.14 | $0.04 | ||
| Q3 25 | $1.13 | $0.10 | ||
| Q2 25 | $0.36 | $-0.01 | ||
| Q1 25 | $0.69 | $0.09 | ||
| Q4 24 | $-0.45 | $0.10 | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | $0.10 | ||
| Q1 24 | $0.82 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $461.5M |
| 总债务越低越好 | — | $462.3M |
| 股东权益账面价值 | $540.7M | $389.7M |
| 总资产 | $1.4B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 1.19× |
8季度趋势，按日历期对齐
现金及短期投资ANIPPENG
| Q4 25 | $285.6M | $461.5M | ||
| Q3 25 | $262.6M | $453.8M | ||
| Q2 25 | $217.8M | $735.5M | ||
| Q1 25 | $149.8M | $647.0M | ||
| Q4 24 | $144.9M | $393.7M | ||
| Q3 24 | $145.0M | $389.5M | ||
| Q2 24 | $240.1M | $467.5M | ||
| Q1 24 | $228.6M | — |
总债务ANIPPENG
| Q4 25 | — | $462.3M | ||
| Q3 25 | — | $461.8M | ||
| Q2 25 | — | $659.5M | ||
| Q1 25 | — | $658.8M | ||
| Q4 24 | — | $658.1M | ||
| Q3 24 | — | $657.3M | ||
| Q2 24 | — | $667.0M | ||
| Q1 24 | — | — |
股东权益ANIPPENG
| Q4 25 | $540.7M | $389.7M | ||
| Q3 25 | $505.8M | $394.2M | ||
| Q2 25 | $436.8M | $584.8M | ||
| Q1 25 | $418.6M | $602.5M | ||
| Q4 24 | $403.7M | $400.4M | ||
| Q3 24 | $405.9M | $391.4M | ||
| Q2 24 | $455.8M | $423.4M | ||
| Q1 24 | $452.0M | — |
总资产ANIPPENG
| Q4 25 | $1.4B | $1.6B | ||
| Q3 25 | $1.4B | $1.6B | ||
| Q2 25 | $1.3B | $1.8B | ||
| Q1 25 | $1.3B | $1.8B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | — |
负债/权益比ANIPPENG
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 1.13× | ||
| Q1 25 | — | 1.09× | ||
| Q4 24 | — | 1.64× | ||
| Q3 24 | — | 1.68× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $31.1M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $28.2M |
| 自由现金流率自由现金流/营收 | 11.8% | 8.2% |
| 资本支出强度资本支出/营收 | 0.5% | 0.8% |
| 现金转化率经营现金流/净利润 | 1.10× | 5.89× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $116.3M |
8季度趋势，按日历期对齐
经营现金流ANIPPENG
| Q4 25 | $30.4M | $31.1M | ||
| Q3 25 | $44.1M | $-70.4M | ||
| Q2 25 | $75.8M | $92.8M | ||
| Q1 25 | $35.0M | $72.9M | ||
| Q4 24 | $15.9M | $13.8M | ||
| Q3 24 | $12.5M | — | ||
| Q2 24 | $17.4M | $57.9M | ||
| Q1 24 | $18.3M | — |
自由现金流ANIPPENG
| Q4 25 | $29.1M | $28.2M | ||
| Q3 25 | $38.0M | $-73.4M | ||
| Q2 25 | $71.8M | $90.9M | ||
| Q1 25 | $32.5M | $70.5M | ||
| Q4 24 | $13.5M | $12.0M | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | $48.9M | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPPENG
| Q4 25 | 11.8% | 8.2% | ||
| Q3 25 | 16.7% | -21.7% | ||
| Q2 25 | 34.0% | 28.0% | ||
| Q1 25 | 16.5% | 19.3% | ||
| Q4 24 | 7.1% | 3.5% | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | 16.3% | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPPENG
| Q4 25 | 0.5% | 0.8% | ||
| Q3 25 | 2.7% | 0.9% | ||
| Q2 25 | 1.9% | 0.6% | ||
| Q1 25 | 1.3% | 0.6% | ||
| Q4 24 | 1.3% | 0.5% | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | 3.0% | ||
| Q1 24 | 3.3% | — |
现金转化率ANIPPENG
| Q4 25 | 1.10× | 5.89× | ||
| Q3 25 | 1.66× | -7.47× | ||
| Q2 25 | 8.87× | 34.88× | ||
| Q1 25 | 2.23× | 9.02× | ||
| Q4 24 | — | 2.65× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 10.30× | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PENG
| Integrated Memory Segment | $171.6M | 50% |
| Advanced Computing Segment | $115.7M | 34% |
| Optimized LED Segment | $55.7M | 16% |
